Summary & Overview
CPT 0272U: Versiti Comprehensive Bleeding Disorder Panel, NGS Genetic Test
CPT code 0272U designates the Versiti™ Comprehensive Bleeding Disorder Panel, a Proprietary Laboratory Analyses (PLA) test that uses next-generation sequencing of 60 genes plus PLAU duplication/deletion analysis to evaluate inherited bleeding disorders. The code is specific to a single manufacturer/laboratory offering and captures a multi-gene molecular diagnostic service that can inform differential diagnosis in symptomatic patients and familial risk assessment. Nationally, PLA codes like 0272U matter because they identify vendor-specific tests with distinct clinical value and billing considerations compared with non-proprietary molecular panels. Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn the clinical scope of the panel, typical sites of service and specimen types, the payer landscape covered by the analysis, and practical coding context such as applicable modifiers (list provided separately). The publication summarizes benchmarks and policy-relevant issues for proprietary molecular diagnostics, outlines common administrative considerations for laboratory billing, and provides a concise clinical context to support coding accuracy and payer communication. Data not available in the input for taxonomies, specific ICD-10 pairings, related codes, or payer-specific coverage policies is noted where applicable.
Billing Code Overview
CPT code 0272U is a Proprietary Laboratory Analyses (PLA) code for the Versiti™ Comprehensive Bleeding Disorder Panel performed by Versiti™ Diagnostic Laboratories. The test uses next-generation sequencing (NGS) to analyze 60 genes associated with inherited bleeding disorders that affect platelet function or the coagulation cascade, and it includes duplication/deletion analysis of the PLAU gene.
-
Service type: Clinical genetic testing using NGS with targeted gene sequencing and copy-number (duplication/deletion) analysis for a specified proprietary panel.
-
Typical site of service: Clinical laboratory; specimens may include blood, buccal swab, or amniotic fluid.
-
Clinical purpose: The panel aids in differential diagnosis for symptomatic patients and in evaluation of familial risk for inherited bleeding conditions.
Clinical & Coding Specifications
Clinical Context
A symptomatic patient with unexplained mucocutaneous bleeding, easy bruising, heavy menstrual bleeding, recurrent epistaxis, or a family history of inherited bleeding disorders is evaluated. A hematologist orders the Versiti™ Comprehensive Bleeding Disorder Panel (0272U) to identify pathogenic variants in 60 genes associated with platelet function and coagulation, and to detect PLAU gene duplication/deletion. Specimen types include peripheral blood, buccal swab, or amniotic fluid. The clinical workflow: initial clinical assessment and coagulation screening tests (CBC, PT/INR, aPTT, fibrinogen, platelet function assays) are performed; if results are inconclusive or genetic confirmation/ familial risk assessment is needed, the provider obtains informed consent for genetic testing, collects the specimen, and sends it to Versiti™ Diagnostic Laboratories. Results are reviewed by the ordering clinician and incorporated into diagnosis, counseling, family testing decisions, and treatment planning (including periprocedural management and targeted therapies). Typical site of service is an outpatient clinic, hospital outpatient laboratory, or specialized genetic testing laboratory facility. Common payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA plans, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional component (interpretation) provided by the laboratory director or pathologist separate from the technical testing. |